Boosting ADR Reporting: Assessing Knowledge, Attitude, and Practices Among UAE Hospital Pharmacists

By Staff Writer

August 2, 2023

A recent study aimed to evaluate the knowledge, attitudes, and practices (KAP) of hospital pharmacists in the UAE regarding Adverse Drug Reaction (ADR) reporting and the barriers to implementing a Pharmacovigilance (PV) system.

Although pharmacists generally display a positive attitude towards ADR reporting, the level of reporting remains low, which may be due to a lack of knowledge about PV and ADRs, including what, where, and when to report.

Interestingly, findings showed that gender does not affect awareness of PV and ADR reporting, but educational level and years of experience do. Hospital pharmacists with less than five years of experience lack the expertise of those with 10-14 years of experience in PV and ADR reporting.

Despite observing ADRs, only half of the participants reported them. This underreporting could be due to poor time management, lack of awareness of the reporting process, difficulties in accessing ADR reports, and poor patient-pharmacist communication.

They also found that the role and years of experience influence the likelihood of ADR reporting. Clinical pharmacists and inpatient pharmacists are more likely to engage in PV due to their direct patient care experience.

In terms of barriers, over half of the pharmacists cited a lack of knowledge about the reporting process. Fear of repercussions from management and legal culpability were also mentioned.

To improve ADR reporting, they recommend incentives for reporting, conducting workshops and ongoing education, providing legal protection, and ensuring easy online access to ADR forms.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.